Rhodiola Rosea: What the Research Actually Shows

Most Rhodiola rosea trials are small, short and methodologically mixed, so the findings below should be read as preliminary signals rather than settled conclusions.

The short answer

Rhodiola rosea is a herb marketed mainly for fatigue, stress and physical or mental performance. Across the published research, the most consistent signal is a modest reduction in self-reported fatigue, especially mental fatigue under stress, and some athletic studies report small improvements in endurance markers. But the evidence base is genuinely weak: trials are small, short, often industry-linked and methodologically mixed, and one systematic review concluded that every included fatigue study carried a high or unclear risk of bias [Ishaque 2012]. Rhodiola is not an established treatment for any disease. If you want a fair summary, it is: plausible, mildly suggestive for fatigue and stress, far from proven, and complicated by serious product-quality problems.

What Rhodiola rosea actually is

Rhodiola rosea (also called golden root, roseroot or Arctic root) is a flowering plant from cold, high-altitude regions of Europe, Asia and North America. The root and rhizome have a long history of traditional use in Scandinavia, Russia and parts of Asia for tiredness and resilience to harsh conditions.

The compounds most often credited with its effects are:

• Rosavins (rosavin, rosin, rosarin) — a group considered relatively specific to Rhodiola rosea, which is why they are used as marker compounds to distinguish it from related species.
• Salidroside (also called rhodioloside) — a phenylethanoid glycoside found in R. rosea and other Rhodiola species.

Most clinical research has used a standardised extract called SHR-5, typically standardised to around 3% rosavins and 1% salidroside [Olsson 2009]. This ratio is worth remembering, because it becomes important later when we look at product quality.

Rhodiola is usually classed as an "adaptogen" — a term we will return to, because it carries less scientific weight than marketing implies.

The claims you will see

Online and on packaging, Rhodiola rosea is promoted for a wide range of outcomes. The most common are:

• Reducing fatigue and exhaustion
• Improving resilience to stress and lowering "burnout"
• Lifting low mood
• Improving cognitive performance, concentration and mental stamina
• Enhancing physical and athletic performance and recovery

These are appealing, broad and overlapping claims, which is itself a warning sign. When a single product is sold for fatigue, stress, mood, focus and athletic output at once, the honest question is not "does it work" but "what has actually been measured, in whom, and how well". Our guide to how "evidence-based" gets misused covers why catch-all claims rarely survive scrutiny.

What the trials actually show

Fatigue

Fatigue is where Rhodiola has the most supportive data, and even here it is shaky. A systematic review by Ishaque and colleagues found 11 eligible trials. Two of six trials in physical fatigue and three of five in mental fatigue reported a benefit, but the authors stressed that all included studies had either a high risk of bias or reporting flaws that prevented a clear judgement of validity, and that the overall picture was contradictory [Ishaque 2012].

Individual trials of the SHR-5 extract are frequently cited. A double-blind study in students during an examination period reported improvements in physical fitness, mental fatigue and well-being [Spasov 2000], and a parallel-group trial in adults with stress-related fatigue reported reduced fatigue and lower morning cortisol response [Olsson 2009]. These are reasonable signals, but the samples are small (often 40 to 60 people), the follow-up is short, and several were conducted by or with the extract manufacturer.

Stress and burnout

A multicentre, open-label trial in people with burnout symptoms reported improvements across fatigue, mood and quality-of-life measures over 12 weeks [Kasper 2017]. The signal is encouraging, but "open-label" means neither participants nor investigators were blinded and there was no placebo group, so expectation effects cannot be ruled out. A 2022 review concluded that the clinical evidence for life-stress symptoms is "encouraging" while still acknowledging the limitations of the underlying trials [Ivanova Stojcheva 2022].

Mood

For depression, the most informative study is a randomised, placebo-controlled trial comparing Rhodiola, the antidepressant sertraline, and placebo in mild-to-moderate major depression. All three groups improved, with no statistically significant difference between them, although Rhodiola was better tolerated than sertraline [Mao 2015]. With only 57 participants, this was explicitly a proof-of-concept study and cannot support a claim that Rhodiola treats depression.

Exercise and cognitive performance

A 2025 systematic review and meta-analysis of 26 trials in 668 mostly young, healthy participants reported small improvements in VO2 max, time to exhaustion and time-trial performance, plus changes in some oxidative-stress and muscle-damage markers. The authors were explicit that heterogeneity across studies "warrants cautious interpretation" [Wang 2025]. Effect sizes were generally small, and what these laboratory markers mean for real-world training or competition is far from clear. If you are interested in the broader context, see what recovery actually means.

Cognitive findings — attention, processing speed, short-term memory — come largely from the same small SHR-5 trials in students and shift workers and share the same limitations.

A second systematic review of randomised trials reached a similar overall verdict: there are some positive findings, but the methodological quality is too limited to draw firm conclusions [Hung 2011]. To understand why study design matters this much, see how to read a clinical trial.

The "adaptogen" concept

Rhodiola is almost always described as an "adaptogen" — a substance said to help the body "adapt" to stress and restore balance. The term originated in mid-20th-century Soviet research and is widely used in herbal pharmacology to group plants such as Rhodiola, ginseng and Eleutherococcus [Panossian 2009].

It is important to be clear about its status. "Adaptogen" is a pharmacological and traditional-use concept, not a regulated medical category in the EU or UK, and it is not recognised by conventional medicine as a defined drug class. The European Medicines Agency has at times debated the term and ultimately approved Rhodiola's traditional use without endorsing "adaptogen" as a proven mechanism [EMA 2011]. In practice, "adaptogen" on a label tells you how a product is being marketed, not that a specific clinical effect has been demonstrated.

This matters because the word does a lot of persuasive work. A claim that something "helps you adapt to stress" is vague enough to be hard to test and hard to disprove, which is exactly the kind of framing worth treating with caution.

Standardisation and product-quality problems

Even setting aside the clinical questions, Rhodiola has a specific and well-documented problem: many products on the market are not what they claim to be.

When researchers analysed around 40 commercial Rhodiola products sold to European buyers, roughly one fifth of products labelled as Rhodiola rosea contained no detectable rosavin — the marker compound used to confirm the species — and many of the rest were lower in rosavin than registered medicinal products, suggesting adulteration with other, cheaper Rhodiola species such as R. crenulata [Booker 2016]. Other market analyses have found commercial products with rosavin and salidroside levels far from their label claims, substitution with different species, and even adulteration with synthetic compounds.

Several factors drive this:

• Species substitution. Related Rhodiola species are visually and chemically similar but lack the characteristic rosavins, and are cheaper.
• Natural variability. Altitude, soil and climate strongly affect a plant's chemistry, so even genuine R. rosea varies batch to batch.
• Light regulation. As a food supplement (rather than a registered medicine), a Rhodiola product faces far lower verification requirements. Our explainer on how supplements are regulated covers why "supplement" and "medicine" are held to very different standards.

The practical consequence is stark: even if Rhodiola has real, modest effects at the studied doses, a randomly chosen supplement may contain little active material, the wrong species, or undisclosed additions. In the UK, products registered under the Traditional Herbal Registration (THR) scheme have met defined quality standards; that registration is the most reliable quality signal available, even though it certifies traditional use and manufacturing quality rather than proven efficacy.

Dose and safety

Most trials have used roughly 200 to 600 mg per day of a standardised SHR-5-type extract (around 3% rosavins, 1% salidroside), often split into one or two doses taken earlier in the day [Olsson 2009][Spasov 2000]. There is no established "optimal" dose, and higher is not demonstrably better.

On safety, Rhodiola is generally well tolerated in short-term studies. Reported side effects are usually mild and may include:

• Dizziness, dry mouth or excess saliva
• Headache
• Restlessness, irritability or disturbed sleep (taking it late in the day may worsen this)
• Occasionally, gastrointestinal upset

Important cautions:

• Limited long-term data. Most trials run for weeks, not months or years, so long-term safety is not well characterised [NCCIH 2020].
• Medication interactions. Data are limited, but caution is advised with serotonergic antidepressants (a theoretical serotonin-syndrome concern), and there are reports relating to other medicines such as some blood-pressure drugs [EMA 2011]. Episodes of agitation have been described in people prone to bipolar disorder.
• Pregnancy and breastfeeding. Safety has not been established, so avoidance is the standard advice.
• Existing conditions. Anyone with a diagnosed mental-health condition, cardiovascular disease or other ongoing illness should seek professional advice before use.

These are reasons to involve a pharmacist or doctor, not reasons to assume the herb is dangerous; the honest position is that we lack the data to be confident either way over the long term.

The measured bottom line

Rhodiola rosea is one of the more plausible herbal supplements for fatigue and stress, but "plausible" is not "proven". The research suggests a possible modest benefit for self-reported fatigue, particularly mental fatigue under stress, with weaker and more uncertain signals for mood and exercise performance. Trials are consistently small, short and of variable quality, and several are linked to extract manufacturers [Ishaque 2012][Hung 2011].

Layered on top of the thin evidence is a real-world quality problem: a substantial share of products are mislabelled, under-dosed or adulterated [Booker 2016]. If you choose to try Rhodiola, a registered traditional herbal product is the most defensible option, expectations should be modest, and it should not replace sleep, training, workload management or appropriate medical care. It does not treat or prevent disease, and it is not a shortcut around the basics. Speak to a healthcare professional first, especially if you take other medication or have an existing condition.

Related Proco pages

• How supplements are regulated
• What recovery actually means
• How to read a clinical trial
• How "evidence-based" gets misused

Sources

If you are considering Rhodiola rosea, particularly alongside prescription medication or an existing health condition, speak to a pharmacist or doctor first.